Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC).
Richard M. Goldberg
Consultant or Advisory Role - Amgen; Genentech; Lilly; MedImmune
Research Funding - Bayer; Enzon; Sanofi
Chris R. Garrett
No relevant relationships to disclose
Noah C. Berkowitz
Employment or Leadership Position - Enzon
Stock Ownership - Enzon
Tanios S. Bekaii-Saab
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech
Honoraria - Amgen; Bristol-Myers Squibb; Genentech
Theresa Ryan
No relevant relationships to disclose
George A. Fisher
No relevant relationships to disclose
Sally Clive
No relevant relationships to disclose
Petr Kavan
No relevant relationships to disclose
Einat Shmueli
No relevant relationships to disclose
Aby Buchbinder
Employment or Leadership Position - Enzon
Stock Ownership - Enzon